Paul Ashton
President & Chief Executive Officer Inflammasome Therapeutics
Seminars
Thursday 5th February 2026
Advancing Inflammasome-Targeted Therapeutics: A Novel Pathway Beyond Amyloid & Alpha-Synuclein
11:30 am
- Leveraging decades of safety data from nucleoside reverse transcriptase inhibitor analogues to accelerate development and reduce risk in Alzheimer’s, Parkinson’s, and MS
- Demonstrating compelling real-world and preclinical evidence showing up to 75% reduced incidence of neurodegenerative disease and robust efficacy in gold-standard models
- Positioning inflammasome modulation as a broad, diseaseagnostic strategy with potential to transform treatment timelines and bypass limitations of single-pathway targets
